Groupe Sartorius Stedim Biotech information financire trimestrielle janvier mars 2010

Regulatory News:

L'information financire trimestrielle de janvier mars 2010 du Groupe Sartorius Stedim Biotech (Paris:DIM) est dsormais disponible sur www.sartorius-stedim.com.

Elle comporte:

- l'volution des activits au cours du premier trimestre et les perspectives de l'exercice 2010 du Groupe Sartorius Stedim Biotech

- les tats financiers consolids au 31 mars 2010

A Profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of ?turning science into solutions.?

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approximately 2,400 people, and in 2009 earned sales revenue of 401.2 million euros.